KROS in “GLP-1 Eats Everything”
Keros Therapeutics, Inc.
Keros is developing muscle-preservation therapies that could complement GLP-1 drugs by limiting the lean-mass loss associated with rapid weight reduction.
KROS impact map — “GLP-1 Eats Everything”
How this story travels from the headline to KROS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading KROS impact map…
Price history, marked with story events
Aug 25, 2025 – Aug 26, 2026 · 250 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Keros is developing muscle-preservation therapies that could complement GLP-1 drugs by limiting the lean-mass loss associated with rapid weight reduction.
Read the full GLP-1 Eats Everything story